Voyager Therapeutics
VYGR
110 hedge funds and large institutions have $211M invested in Voyager Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 17 closing their positions.
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
4% more funds holding
Funds holding: 106 → 110 (+4)
6% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 33
0.3% more ownership
Funds ownership: 61.73% → 62.03% (+0.3%)
31% less capital invested
Capital invested by funds: $308M → $211M (-$96.5M)
51% less call options, than puts
Call options by funds: $368K | Put options by funds: $748K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.06M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.07M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$1.95M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.82M |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.47M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.94M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.38M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.15M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.75M |
VYGR Hedge Fund Activity: Q3 2023 in Review
110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2023, worth a combined $211M — down 31% from $308M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VYGR positions and 17 closed out — a net gain of 4 holders — while 35 added to existing stakes and 33 trimmed.
The largest buyer was Armistice Capital, adding an estimated $5.06M. The largest seller was Morgan Stanley, cutting an estimated $4.47M.
- 110 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2023, up from 106 in Q2 2023.
- Funds reported $211M of Voyager Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
- 21 funds opened new Voyager Therapeutics positions in Q3 2023 and 17 closed out, a net change of +4 holders.
- The largest Voyager Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $5.06M added.
- The largest Voyager Therapeutics seller in Q3 2023 was Morgan Stanley, an estimated $4.47M sold.
Based on aggregated 13F filings for Q3 2023.